Study Year of
publication 		Country Study design Sample Age
(years) 		Male/female Systemic
disease 		Intervention Follow-up
(months) 		Assessed PPD
(mm)
Mean (SD)
Guerrero et al. [14] 2005 UK Parallel, double-blind, placebo-controlled, randomized Test:
20 		Test:
29.8 (6.45) 		Test:
4/16 		No Test: SRP + 500 mg AMX/500 mg MET
7 days 		6 Moderate
(PD = 4 to 6);
severe
(PD ≥ 7)
Control:
21 		Control:
31.86 (5.22) 		Control:
9/21
Casarin et al. [32] 2012 Brazil Parallel, masked, placebo-controlled randomized Test:
12 		Test:
28.8 (6.2) 		Test:
3/9 		No Test: SRP + 375 mg; AMX/250 mg MET
7 days 		3, 6 Moderate
(PD = 5 to 6);
severe
(PD ≥ 7)
Control:
12 		Control:
28.3 (5.9) 		Control:
5/7
Mestnik et al. [35] 2010 Brazil Parallel, double-blind, placebo-controlled, randomized Test:
15 		Test:
26.8 (3.9) 		Test:
6/9 		No Test: SRP + 500 mg AMX/400 mg MET
14 days 		3 Moderate
(PD = 4 to 6);
severe
(PD ≥ 7)
Control:
15 		Control:
27.6 (3.5) 		Control:
4/11
Varela et al. [36] 2011 Brazil Parallel, double-masked, placebo-controlled, randomized Test:
18 		Test:
33.1 (5.1) 		Test:
8/10 		No Test: SRP + 500 mg AMX/250 mg MET
10 days 		3, 6 Moderate
(PD = 4 to 6);
severe
(PD ≥ 7)
Control:
17 		Control:
32.1 (3.9) 		Control:
4/13
Ercan et al. [48] 2015 Turkey Parallel, placebo-controlled, Test:
15 		Test:
31.3 		Test:
6/9 		No Test: SRP + 500 mg AMX/500 mg MET 3 PPD ≥ 3
Control:
15 		Control:
31.7 		Control:
4/11
Rodrigues et al. [49] 2012 Brazil Parallel, randomized Test:
15 		Test:
27.73 (5.84) 		Test:
11/4 		No Test: SRP + 500 mg AMX/400 mg MET
7 days 		3, 6 PPD ≥ 3
Control:
15 		Control:
27.73 (5.84) 		Control:
11/4

SRP = scaling root planning; AMX = amoxicillin; MET = metronidazole; PPD = probing pocket depth; PD = probing depth.